Skip to content
PeptideWADA ProhibitedCompare

PEG-MGF

Also known as: Pegylated MGF, PEG Mechano Growth Factor, PEGylated Mechano Growth Factor, PEG IGF-1Ec

4
1 · Natty510 · Enhanced

Lower numbers = closer to natural. Higher numbers = more enhanced.

Why this rating?

PEG-MGF is a pegylated form of Mechano Growth Factor (MGF), the IGF-1Ec splice variant of IGF-1 that muscle expresses during repair after mechanical loading and that has anabolic effects. Native MGF is rapidly metabolised in vivo (a very short half-life), so PEGylation is used to extend its circulation for systemic dosing. It is banned by WADA (as a growth factor / IGF-1-family peptide). Rated 4 alongside MGF: mechanistically promising for satellite-cell/repair signalling but with thin human proof, and at least one paper has raised a carcinogenicity concern. Not an androgen, so no HPTA effect.

Overview

A pegylated version of Mechano Growth Factor (MGF). MGF is a naturally occurring 24-amino-acid peptide - the C-terminal fragment produced when insulin-like growth factor 1 (IGF-1) is spliced/cleaved to the "IGF-1Ec" isoform - which muscle expresses during repair after physical activity and which has anabolic effects. Because native MGF is rapidly broken down in the body, synthetic versions attach polyethylene glycol (PEG) to the peptide (and often use D-amino acid substitutions in the central QRRK region) to resist metabolism, so PEG-MGF can act systemically rather than only locally.

Important Warnings

  • •WADA prohibited (S2 growth factors) - will cause a positive test
  • •Avoid with a personal/family history of cancer - a carcinogenicity concern has been published for MGF
  • •Human hypertrophy evidence for injected MGF is thin - physique claims are largely extrapolated
  • •No validated human dose - community figures only
  • •Research-chemical quality varies - verify it is the PEGylated form

Purpose & Use Cases

Systemic MGF Exposure

PEGylation extends the very short native half-life so the peptide can be dosed for a body-wide effect rather than only a fleeting local one at the injection site.

Muscle Repair & Recovery

Community use targets faster recovery by reinforcing the satellite-cell/repair signalling that mechanical muscle damage normally triggers.

Adjunct to the GH / IGF-1 Axis

Layered onto GH-axis or IGF-1 protocols to add the local muscle-repair arm that GH alone does not fully cover.

Benefits

  • Extended half-life over native MGF (via PEGylation) for systemic dosing
  • Targets the satellite-cell / muscle-repair arm of the IGF-1 family
  • Anabolic effects tied to muscle repair after mechanical loading
  • Does not suppress testosterone - no PCT required
  • Not an androgen - no aromatisation, DHT or hair-loss considerations

Good to Know

It is an IGF-1 splice variant, PEGylated to last longer

MGF = IGF-1Ec: a C-terminal peptide from spliced/cleaved IGF-1, expressed during muscle repair after loading and anabolic in effect. Native MGF is rapidly metabolised in vivo, so PEG-MGF attaches polyethylene glycol (and stabilising D-amino acids in the central QRRK region) to extend circulation and allow systemic - not just local - dosing.

Native vs PEG changes how it is used

Native MGF survives only briefly and must be injected locally within minutes of training for a site-specific effect. PEG-MGF is engineered to circulate for a systemic effect, so it is dosed 2-3x weekly rather than needing that within-minutes window - though most community protocols still time each dose within an hour or two of training rather than detaching it from the workout entirely. Buying the wrong one for your intended protocol is a common mistake.

Evidence is thinner than the hype - and there is a cancer flag

Cell-culture work (Kandalla et al. 2011) found the MGF E-peptide activates human muscle progenitor cells, but a later study (Fornaro et al. 2014) found synthetic MGF peptide had no apparent effect on myoblasts or primary muscle stem cells - the underlying receptor was never definitively identified, and robust human hypertrophy trials of injected MGF are essentially absent. Separately, a review of IGF-1 splice-variant biology (Kasprzak & Szaflarski 2020) discusses MGF/IGF-1Ec's potential role in several human tumor types, reinforcing the standard IGF-1-family caution against use with any cancer history.

WADA-banned even though it is "just a peptide"

MGF and PEG-MGF are prohibited by WADA under S2 as growth factors, in the same section that captures IGF-1 and its analogues. Tested athletes should treat it exactly like IGF-1 - not a grey-area recovery aid in a doping-control sense.

Dosage Guidelines

Experience LevelDosage Range
Beginner300 – 500 mcg/week
Intermediate500 – 900 mcg/week
Advanced900 – 1500 mcg/week
Frequency
Community protocols dose 200-400mcg per injection, 2-3x per week on training days (commonly within 1-2 hours post-workout) - it is the WEEKLY TOTAL, not the per-shot amount, that matters for the systemic PEGylated form. PEGylation removes native MGF's within-minutes injection window, but most protocols still time doses around training rather than at a fixed time of day.
Typical Cycle Length
4 – 6 weeks
Notes

There is no validated human dose - these ranges reflect community/vendor practice, not clinical data. Community sources commonly suggest 4-6 weeks on, then at least 4-6 weeks off, to avoid receptor desensitization. Reconstitute with bacteriostatic water and refrigerate; use within a few weeks of reconstitution. Research-chemical identity (native vs PEG, sequence fidelity) and purity vary widely by source.

Half-Life

Native MGF is metabolised within minutes and acts only locally; PEGylation is commonly cited (by vendors/community sources) as extending this to roughly 1-3 days for systemic exposure, but that specific figure is a community estimate rather than a published pharmacokinetic study.

Side Effects

Injection Site Reaction

common
Severity
1/5

Redness, itching or a mild lump at the injection site.

Mitigation

Rotate sites; use sterile technique.

Flushing / Warmth

uncommon
Severity
1/5

Transient flushing or warmth after injection.

Mitigation

Usually settles on its own; lower dose if bothersome.

Theoretical Growth-Promoting / Carcinogenicity Concern

rare
Severity
3/5

As an IGF-1-family growth factor that stimulates cell proliferation, chronic use carries a theoretical concern about promoting growth of existing/abnormal cells; at least one research paper has specifically raised a carcinogenicity concern about MGF.

Mitigation

Avoid with a personal/family history of cancer. Keep doses and cycle lengths conservative.

Sourcing / Purity Risk

common
Severity
2/5

As an unregulated research peptide, actual content and whether it is truly the PEGylated form vary widely by source.

Mitigation

Use tested product with a certificate of analysis.

General Mitigation Strategies

PEG-MGF is generally reported as well tolerated at community doses, with injection-site reactions the main complaint. Rotate sites, keep doses conservative, and avoid if you have a cancer history given the shared IGF-1-family growth mechanism and a published carcinogenicity concern. The biggest practical issue is product quality - verify source, purity and that it is the PEGylated (not native) peptide. Human hypertrophy evidence for injected MGF is thin, so temper expectations.

Post Cycle Therapy (PCT)

✓PCT Not Required

Not an androgen. Does not affect the HPTA or testosterone. No PCT required.

How It Works

MGF is the IGF-1Ec splice variant: the same IGF-1 gene product cleaved to yield a distinct 24-amino-acid E-domain peptide that is expressed during muscle repair following mechanical loading and exerts anabolic effects, classically framed as activating satellite (muscle stem) cells to support regeneration. Native MGF is rapidly metabolised in vivo, which limits its therapeutic window; PEGylation of the tyrosine residue (with stabilising D-amino acids at positions 13-16 in the central "QRRK" domain) improves metabolic stability so the peptide survives long enough for systemic exposure. It is a member of the IGF-1 family, distinct from IGF-1 LR3/DES.

Fundamentals

Reference on the practices relevant to PEG-MGF: how they are done and where they go wrong. Not a recommendation to use it.

Reconstitution & concentration math→

Turning this powder into a measured dose

Sterile technique & injection-site infection→

Avoiding abscesses and cellulitis

Bloodwork: what to measure and when→

The markers that matter here

Warning signs & when to seek care→

When to stop and get help

WADA Status

⛔Prohibited by WADA
Category: S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics
In-Competition: ProhibitedOut-of-Competition: Prohibited

PEG-MGF (like MGF and IGF-1) is prohibited at all times under WADA S2 as a growth factor.

References

Last updated: July 18, 2026